With a move from St. Louis to the University of Maryland, Baltimore, KaloCyte CEO Elaine Haynes said the team would be in one space within a unique university environment, and close to federal partners.

Research and startups are each important ingredients as the University of Maryland, Baltimore works to build a biotech community. In the case of recent news from KaloCyte, a mix involving both came with one move.

As announced last week, the team that is commercializing a synthetic blood product relocated from St. Louis to downtown Baltimore, with the company taking up residence at UMB and joining the University of Maryland BioPark as an affiliate.

Nearby, at the campus’ University of Maryland School of Medicine (UMSOM), cofounder Chief Scientific Officer Dr. Allan Doctor is directing the recently formed Center for Blood Oxygen Transport & Hemostasis (CBOTH), while cofounder Dr. Dipanjan Pan is leading nanobiofabrication at the center and become a professor at UMSOM and University of Maryland, Baltimore County.

Read the full article from Technical.ly Baltimore.